---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019362"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:58:09.189952+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets

## Summary
- Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.
- Seven non-binding term sheets with four partners could yield up to $410M milestones plus future royalties.
- Lead asset EB-003 advancing toward IND filing and Phase 1 trial.
- Raised $4.5M from warrant exercises in Q1.
- Drug discovery platform generated >1,000 proprietary candidates across seven molecule classes.

## SEC filing metadata
- accession: 0001493152-24-019362
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/0001493152-24-019362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019362
- JSON: https://secwatch.observer/filing/0001493152-24-019362.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019362.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income $2.46 million, EPS $0.61.
  - Period: the first quarter ended March 31, 2024
  - Net income: $2.46 million
  - EPS: $0.61
  - Result: reported results
  source text: Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/0001493152-24-019362-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.